Rodrigo Pirmez

ORCID: 0000-0002-5644-4351
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hair Growth and Disorders
  • Dermatologic Treatments and Research
  • Autoimmune and Inflammatory Disorders
  • Autoimmune Bullous Skin Diseases
  • Genetic and rare skin diseases.
  • melanin and skin pigmentation
  • Skin Protection and Aging
  • Acne and Rosacea Treatments and Effects
  • Dermatology and Skin Diseases
  • RNA regulation and disease
  • Nail Diseases and Treatments
  • Cutaneous lymphoproliferative disorders research
  • Body Contouring and Surgery
  • Cancer and Skin Lesions
  • Skin and Cellular Biology Research
  • Dermatological and Skeletal Disorders
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Artificial Immune Systems Applications
  • Eosinophilic Disorders and Syndromes
  • Peripheral Neuropathies and Disorders
  • Facial Rejuvenation and Surgery Techniques
  • Inflammatory Myopathies and Dermatomyositis
  • Dyeing and Modifying Textile Fibers
  • Dupuytren's Contracture and Treatments
  • Contact Dermatitis and Allergies

Institute of Dermatology
2016-2025

Universidade do Estado do Rio de Janeiro
2015-2024

Fundação CECIERJ
2024

Centro Brasileiro de Estudos em Dermatologia
2021

Santa Casa de Misericórdia de Passos
2015-2020

Skin Care and Laser Physicians of Beverly Hills
2018

Hospital Central da Polícia Militar
2018

Advanced Dermatology
2017

Universidade Federal do Rio de Janeiro
2010-2015

Hospital Universitário Clementino Fraga Filho
2012

The frequency of different types alopecia is not clearly reported in recent studies.To analyze the patients consulting at specialist hair clinics (SHC) and to assess for global variations.Multicenter retrospective study including data from evaluated referral SHC Europe, America, Africa Australia.A total 2,835 (72.7% females 27.3% males) with 3,133 diagnoses were included (73% non-cicatricial 27% cicatricial alopecias). In all, 57 characterized. most frequent type was androgenetic (AGA)...

10.1159/000496708 article EN Skin Appendage Disorders 2019-01-01

The cutaneous manifestations of COVID-19 may be useful disease markers and prognostic indicators. Recently, postinfectious telogen effluvium trichodynia have also been reported.To evaluate the presence in patients with describe their characteristics relation to other signs symptoms disease.Patients a history presenting clinics group hair experts because and/or scalp were questioned about severity associated symptoms.Data from 128 collected. Telogen was observed 66.3% 58.4%. Trichodynia 42.4%...

10.1016/j.jdin.2021.07.006 article EN cc-by-nc-nd JAAD International 2021-08-02

The objective of our study was to analyze the effectiveness oral minoxidil on frontotemporal hairline in patients with FFA. We conducted a retrospective, descriptive, multicenter 2 Brazilian and 1 Spanish centers. Responses were graded scale 3 positive points. A total 122 included. Subjective improvement density observed 45.1% patients, which categorized as mild (34.4%), moderate (9.0%), excellent (1.6%). Hair improved 57.4% patients' interparietal. Additionally, 25.4% 3.3% experienced...

10.1016/j.ad.2025.02.008 article EN cc-by-nc-nd Actas Dermo-Sifiliográficas 2025-02-01

Isotretinoin is a synthetic retinoid, derived from vitamin A, with multiple mechanisms of action and highly effective in the treatment acne, despite common adverse events, manageable dose-dependent. Dose-independent teratogenicity most serious. Therefore, off-label prescriptions require strict criteria.To communicate experience recommendation Brazilian dermatologists on oral use drug dermatology.Eight experts five universities were appointed by Society Dermatology to develop consensus...

10.1016/j.abd.2020.09.001 article EN cc-by Anais Brasileiros de Dermatologia 2020-10-03

Low-dose oral minoxidil (≤ 5 mg daily) has emerged as an effective off-label treatment for androgenetic alopecia, outperforming topical in terms of adherence. However, the optimal dose not yet been determined, and high doses may cause systemic adverse effects. This retrospective study 57 patients evaluated safety efficacy profile at higher (> mg). Results showed overall improvement hair density between 10-30% most patients, although with variable responses. A total 17.5% experienced...

10.1016/j.ad.2024.12.022 article EN cc-by-nc-nd Actas Dermo-Sifiliográficas 2025-03-01

Frontal fibrosing alopecia (FFA) has become one of the most common causes cicatricial worldwide. However, there is a lack clear aetiology and robust clinical trial evidence for efficacy safety agents currently used treatment. To enable data to be collected worldwide on FFA using criteria assessment methods. A multicentre, international group experts in hair loss was convened by email create consensus recommendations trials. Consensus defined at > 90% agreement each recommended part these...

10.1111/bjd.20567 article EN British Journal of Dermatology 2021-06-09

Frontal fibrosing alopecia (FFA) is considered a variant of lichen planopilaris affecting mainly the frontotemporal hairline. Since first report in 1994, several other clinical features have been associated with disease, such as facial papules (FP). Even though FP linked to vellus hair follicle involvement, how this finding alone could lead formation clinically evident FFA patients had not yet addressed.To describe histopathological findings context and highlight that may be their...

10.1159/000481695 article EN Skin Appendage Disorders 2017-11-03

A recent expert consensus exercise emphasized the importance of developing a global network patient registries for alopecia areata to redress paucity comparable, real-world data regarding effectiveness and safety existing emerging therapies areata.To generate core domains domain items registries.Sixty-six participants, representing physicians, organizations, scientists, pharmaceutical industry, pharmacoeconomic experts, participated in 3-round eDelphi process, culminating face-to-face...

10.1001/jamadermatol.2020.5839 article EN JAMA Dermatology 2021-03-03

Antecedentes y objetivo: los efectos adversos sistémicos son una de las principales limitaciones del uso minoxidil oral a dosis bajas (MODB), especialmente en pacientes con hipertensión arterial o arritmias. El objetivo este estudio fue evaluar la seguridad MODB estos pacientes. Material método: retrospectivo multicéntrico antecedentes arritmias tratados para cualquier tipo alopecia. Resultados: Se incluyó un total 254 [176 mujeres (69,3%) 78 hombres (30,7%)] edad media 56,9 años (rango 19 –...

10.1016/j.ad.2023.07.019 article ES cc-by-nc-nd Actas Dermo-Sifiliográficas 2023-08-30
Coming Soon ...